pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,246 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1212Endpoints919BioPharma Dive354BioSpace335Fierce Biotech315onclive165raps111globenewswire health73
therapy area
allOncology8148Rare Disease1937Cardiology1879Immunology1555Hematology1354Pulmonology1264Vaccines
  • New hepatitis B vaccine guidance prompts analysis of public trust and policy impacts
    The Morning Rounds newsletter examines how the latest recommendations for a hepatitis B vaccine could affect public health outcomes. It highlights recent surveys that show varying levels of confid…
    STAT · 4mo agoNeutral↗ source
  • EPA proposes first rule to flag microplastics and pharmaceuticals in drinking water, alongside $144 million ARPA-H study program
    The Environmental Protection Agency announced a proposed rule that would formally label microplastics and pharmaceutical residues in drinking water as contaminants that merit federal study and trac…
    STAT · 4mo agoRegulatoryNeutral↗ source
← prev
page 127 of 130
next →
fda recalls71
fda medwatch62
fda press38
1261
Psychiatry & CNS889
Ophthalmology521
Pain501
Endocrinology & Metabolism495
Infectious Disease457
  • Adaptyv Bio shares results from its latest AI-driven protein design contest
    Adaptyv Bio, a biotech firm focused on protein engineering, released the outcomes of its newest competition that tests how well artificial‑intelligence models can create novel proteins. The challe…
    Endpoints · 4mo agoNeutral↗ source
  • Google AI clinical director says chatbot can serve as bridge for mental health crises
    Google’s clinical director, Megan Jones Bell, told STAT that the company is working to make its Gemini chatbot a helpful resource for users experiencing mental health crises. She emphasized that th…
    STAT · 4mo agoPositive↗ source
  • STAT seeks reader input on adopting AP’s “healthcare” spelling
    The Associated Press Stylebook recently announced that the term "healthcare" should be written as a single word, updating its long-standing guidance. STAT, which has used the two-word form "health…
    STAT · 4mo agoNeutral↗ source
  • Intellia's single-dose CRISPR therapy cuts hereditary angioedema attacks in Phase 3 trial
    Intellia Therapeutics reported that its gene-editing candidate lonvo-z produced a dramatic reduction in swelling attacks for patients with hereditary angioedema in a Phase 3 study. The single-dose…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Intellia’s CRISPR therapy cuts hereditary angioedema attacks by 87% in Phase 3 trial
    Intellia Therapeutics reported that its experimental CRISPR-based drug lonvo-z met the primary endpoint in a Phase 3 study for hereditary angioedema, a rare swelling disorder. The trial showed an…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Intellia's in-body CRISPR therapy achieves first Phase 3 success
    Intellia announced that its experimental in vivo CRISPR gene‑editing therapy has completed a Phase 3 trial with positive results. This is the first instance of a CRISPR‑based treatment delivered d…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Intellia's single-dose CRISPR therapy slashes hereditary angioedema attacks by 87% in Phase 3 trial
    Intellia Therapeutics reported that its CRISPR-based gene editing drug lonvo-z achieved a dramatic reduction in swelling attacks for patients with hereditary angioedema (HAE) in a Phase 3 study. T…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Sun Pharma to acquire Organon for $11.75 billion in all-cash deal
    Indian pharmaceutical company Sun Pharma announced it will purchase Organon, a company focused on women's health and biosimilars that was spun out of Merck in 2021. The transaction is an all-cash…
    Endpoints · 4mo agoDealPositive↗ source
  • Veradermics reports positive Phase 3 results for oral baldness pill
    Veradermics said its experimental oral formulation of minoxidil met the primary goal of its Phase 3 trial, showing significantly more new hair growth over six months compared with placebo. The dru…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Intellia reports positive Phase 3 readout for CRISPR gene-editing therapy in hereditary angioedema
    Intellia Therapeutics announced that its CRISPR-based therapy achieved a successful readout in a Phase 3 trial for hereditary angioedema, a rare condition marked by sudden, potentially dangerous sw…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • New U.S. hepatitis B vaccine policy targeting only at-risk newborns could raise infant infections and costs, studies warn
    A new U.S. recommendation limits the birth‑dose hepatitis B vaccine to infants who are judged to be at risk of neonatal infection, rather than offering it universally to all newborns. One study co…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Oruka’s experimental psoriasis drug achieves near-complete skin clearance in Phase 2 trial
    Oruka Therapeutics reported that its experimental IL-23 inhibitor ORKA-001 cleared the skin of 40 of 63 patients (about 63%) in a Phase 2 study, achieving a PASI 100 response at 16 weeks. A further…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion to develop improved JAK inhibitor
    Eli Lilly announced Monday it will purchase Ajax Therapeutics, a biotech based in New York and Cambridge, Massachusetts, in a deal valued at up to $2.3 billion. The transaction includes cash up fr…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Eli Lilly to pay up to $2.3B for Ajax's JAK inhibitor in cancer deal
    Eli Lilly announced a new agreement with Ajax Therapeutics to acquire rights to a JAK inhibitor called Kyle LaHucik for cancer treatment. The transaction could be worth up to $2.3 billion, reflect…
    Endpoints · 4mo agoDealPositive↗ source
  • Compass Therapeutics reports secondary endpoint data from pivotal biliary tract cancer trial, shares stock drop
    Compass Therapeutics announced new secondary‑endpoint results from its pivotal bispecific antibody trial in second‑line biliary tract cancer, a year after reporting a Phase 2/3 success. The additi…
    Endpoints · 4mo agoNegative readoutNegative↗ source
  • Oruka's yearly injectable shows 63% complete clearance in mid-stage psoriasis trial
    Oruka Therapeutics reported results from a Phase 2 trial of its long-acting injectable, ORKA-001, in patients with plaque psoriasis. In the study, 63% of participants achieved complete skin cleara…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Supreme Court split on blocking thousands of Roundup cancer lawsuits
    The Supreme Court heard arguments on Monday about whether to block thousands of lawsuits claiming the weedkiller Roundup caused cancer, and the justices appeared divided. The dispute follows a wav…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Erasca reports early trial shows tumor shrinkage in 40% of pancreatic and 62% of lung cancer patients
    Erasca announced that its experimental RAS-targeting oral drug, ERAS-0015, produced tumor reductions in a portion of patients with advanced pancreatic cancer and advanced non-small cell lung cancer…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Erasca releases early-stage RAS drug data amid legal dispute with Revolution Medicines
    Erasca has released early-stage data on its RAS-targeting compound, doing so after receiving a legal threat from rival Revolution Medicines. Revolution recently announced a new drug that revived h…
    Endpoints · 4mo agoNeutral↗ source
  • Thermo Fisher to divest microbiology unit to Astorg for $1.075 billion; Ligand announces purchase of XOMA
    Thermo Fisher Scientific announced it will sell its microbiology business, part of its specialty diagnostics segment, to European private‑equity firm Astorg. The transaction is valued at $1.075 bi…
    Endpoints · 4mo agoDealNeutral↗ source
  • Oruka Therapeutics reports Phase 2 psoriasis results with 63% of patients showing plaque improvement
    Oruka Therapeutics announced results from its Phase 2 trial in moderate to severe plaque psoriasis. The study enrolled 63 patients and 40 of them, about 63.5%, achieved the predefined level of ski…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • AI-driven biotech Fathom Therapeutics secures $47 million Series A funding and rebrands from Atommap
    Fathom Therapeutics, the company formerly known as Atommap, announced that it has closed a $47 million Series A financing round. The capital raise will support the firm’s effort to combine artifici…
    Endpoints · 4mo agoDealPositive↗ source
  • FDA greenlights Motif Neurotech's feasibility trial of brain-implant hat for treatment-resistant depression
    The U.S. Food and Drug Administration has approved Motif Neurotech's request to begin an initial feasibility trial of its brain‑implant device aimed at patients with treatment‑resistant depression.…
    STAT · 4mo agoCRLPositive↗ source